Shared antigen mRNA cancer vaccines, including Moderna’s mRNA KRAS cancer vaccine mRNA-5671, are at the center of the expansion of the 2016 collaboration between Moderna Therapeutics http://( Merck http://( mRNA-5671 will be jointly developed by the two companies in human studies, with plans to conduct also combination studies with additional immuno-oncology therapies. The investigational product encodes for the four most commonly found KRAS mutations, and is designed to target most of the KRAS mutations that occur in NSCLC, colorectal cancer and pancreatic cancer.